Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of

Clinical Trial Summary

Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

See also
Status	Clinical Trial	Phase
Completed	`NCT01559519` - Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy	Phase 4
Terminated	`NCT01846806` - The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.	N/A
Recruiting	`NCT01178372` - Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis	Phase 4
Completed	`NCT00740142` - Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy	Phase 4
Completed	`NCT00914056` - A Study of Controlled Lactulose Withdrawal	N/A
Completed	`NCT00558038` - Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT00986895` - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group	Phase 1
Completed	`NCT00287235` - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)	N/A
Recruiting	`NCT05539027` - Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy	Phase 4
Recruiting	`NCT04096014` - Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy	N/A
Completed	`NCT05526404` - Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Enrolling by invitation	`NCT06367127` - Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
Active, not recruiting	`NCT05425316` - Speech in Hepatic Encephalopathy (HE)
Recruiting	`NCT04415294` - Flicker App for Minimal Hepatic Encephalopathy
Not yet recruiting	`NCT06072521` - Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT02636647` - Fecal Transplant in Recurrent Hepatic Encephalopathy	Phase 1
Withdrawn	`NCT02086825` - A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure	Phase 3
Completed	`NCT01446523` - S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE	N/A
Completed	`NCT01218568` - Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial	N/A

NCT number	NCT05297448
Study type	Interventional
Source	Bausch Health Americas, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	August 3, 2022
Completion date	January 2026

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis — RED-C-3132

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms